Prostate cancer is the most commonly diagnosed cancer in men, accounting for 30 percent of all cancers and second only to lung cancer as a leading cause of cancer deaths. This year, approximately 241,740 men in the United States will be diagnosed with prostate cancer and an estimated 28,170 will die from the disease. During the period of 2004 to 2008, the prostate cancer death rate among African American men was approximately 2.5 times as high as that of Caucasian men. While recent advancements in therapies for metastatic prostate cancer are providing increased hope, there remains no definitive cure for locally advanced or metastatic disease. The Prostate Cancer Research Program prioritizes research that will develop effective therapies for advanced prostate cancer or distinguish between indolent and aggressive disease. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.
PCRP-Supported Key Research Resources
PCRP Perspectives: Keep Informed on Breakthroughs in Prostate Cancer Research
Innovative Minds in Prostate Cancer Today
The IMPaCT 2011 Conference was held March 9-12, 2011 in Orlando, Florida. Click here for more information.
Congressional Appropriations
- $1.13 billion in FY97-11
- $80 million in FY12
Funding Summary
- 2,504 Awards in FY97-11
- Recent Applications Recommended for Funding
- Prostate Cancer Consortium Awards
- Program Portfolio
Integration Panels
